GeoVax Labs Inc. reported financial results for the first quarter of 2025, revealing a net loss of $5.4 million, compared to a net loss of $5.9 million in the same period of 2024. The company achieved $1.6 million in revenue from government contracts associated with the BARDA/RRPV Project NextGen award, in contrast to no reported revenues in the first quarter of 2024. Research and development expenses rose to $5.4 million from $4.4 million in the previous year, driven by costs related to the BARDA/RRPV Project NextGen award, as well as the Gedeptin and GEO-MVA programs. GeoVax's general and administrative expenses increased to $1.7 million from $1.5 million, attributed to higher investor relations consulting costs and stock-based compensation. The company held cash balances of $7.4 million as of March 31, 2025, up from $5.5 million at the end of 2024. Significant business developments include the ongoing progress of the COVID-19 vaccine program, with additional data expected in the second quarter of 2025, and the initiation of the clinical evaluation of GEO-MVA in the second half of 2025. Additionally, Gedeptin is advancing into a Phase 2 clinical trial for recurrent head and neck cancer treatment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.